Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. Review uri icon

Overview

abstract

  • Prostate-specific membrane antigen (PSMA) is a clinically validated target for prostate cancer. A variety of PSMA-based therapies, including radionuclide- and cytotoxic drug-conjugated and cellular immune products, are in development, each with variable advantages and disadvantages. Here we briefly describe the landscape of PSMA-based therapies beyond 177Lu-PSMA-617, which is covered elsewhere. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA) is a protein expressed on most prostate cancer tumors and on limited other areas in the body. It can be targeted to treat prostate cancer using radioactive particles, drugs, or immune agents.

publication date

  • February 27, 2021

Research

keywords

  • Prostate
  • Prostatic Neoplasms

Identity

Scopus Document Identifier

  • 85101668372

Digital Object Identifier (DOI)

  • 10.1016/j.euf.2021.02.006

PubMed ID

  • 33648895

Additional Document Info

volume

  • 7

issue

  • 2